COMP <GO>
INFU vs ABBV // GROSS PROFIT MARGIN
InfuSystems Holdings Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: INFU 4
— ABBV 9
▲ GROSS PROFIT MARGIN LEADER: ABBV
LAST: $14.45 (+0.91%) • MKT CAP: $287.8M
gross-margins
56.00%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
gross-margins
70.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INFU VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INFU | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 56.00% | 70.20% | -14.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 12.80% | 29.00% | -16.20 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 24.5x | 33.3x | -8.80 | INFU | /valuation <GO> |
| Free Cash Flow Yield | 8.29% | 3.47% | +4.82 | INFU | /fcf-yield <GO> |
| Operating Margin | 8.30% | 24.60% | -16.30 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 4.60% | 6.90% | -2.30 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 6.40% | 8.60% | -2.20 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.16 | 5.33 | -0.17 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | INFU | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.6 | 65.1 | -6.52 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 40.4x | 113.1x | -72.70 | INFU | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $287.8M | $513.86B | -$513.57B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INFU REV | ABBV REV | INFU GROSS % | ABBV GROSS % | INFU FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $143.4M | $61.16B | 56.0% | 70.2% | $23.8M | $17.82B |
| FY 2024 | $134.9M | $56.33B | 52.2% | 70.0% | $19.4M | $17.83B |
| FY 2023 | $125.8M | $54.32B | — | — | $11.2M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INFU // BETA —
ABBV // BETA 1.15